{"entity":{"id":"nct05588648","kind":"trial","name":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","aka":[],"tldr":"A phase 1/2 trial of Vactosertib in osteosarcoma, run by MedPacto, Inc., now recruiting.","summary":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma is a phase 1/2 interventional study registered as NCT05588648 by MedPacto, Inc., with 48 participants planned, started 2023-05-01 and due to reach its primary completion in 2025-09. Interventions recorded: Vactosertib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05588648","url":"https://clinicaltrials.gov/study/NCT05588648"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05588648","phase":"1/2","setting":"A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","sponsor":"MedPacto, Inc.","enrolled":48,"outcomes":[]},"route":"/trials/nct05588648/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"vactosertib","kind":"drug","name":"Vactosertib","route":"/drugs/vactosertib/"}]}}